Skip to main content

Table 2 Synergy experiments with HMCLs

From: Targeting phosphoglycerate dehydrogenase in multiple myeloma

A B
CBR5884 NCT-503
Cells Proteosome inhibitor IC50 of PI Fold change in IC50 P value Cells Proteosome inhibitor IC50 of PI Fold change in IC50 P value
- CBR  + CBR - NCT  + NCT
INA6 Carf 1.2 1.1 0.90 0.5074 INA6 Carf 1.2 1.2 0.98 0.8862
BTZ 14.6 16.5 1.13 0.0406 BTZ 15.4 8.6 0.56  < 0.0001
KJON1 Carf 2.4 2.1 0.88 0.1246 KJON1 Carf 2.7 3.3 1.22 0.0186
BTZ 27.4 24.6 0.90 0.1895 BTZ 26.1 19.3 0.74 0.0001
IH1 Carf 5.2 4.1 0.79 0.0058 IH1 Carf 5.6 6.4 1.15 0.0408
BTZ 14.7 12.6 0.86 0.1743 BTZ 12.7 11.1 0.88 0.0258
OH2 Carf 2.5 2.2 0.90 0.3532 OH2 Carf 2.6 2.6 1.01 0.9351
BTZ 11.0 9.2 0.84 0.0472 BTZ 11.5 6.5 0.56  < 0.0001
JJN3 Carf 3.7 2.1 0.58  < 0.0001 JJN3 Carf 3.7 5.8 1.59  < 0.0001
BTZ 17.4 11.4 0.66  < 0.0001 BTZ 16.7 15.4 0.92 0.2634
RPMI8226 Carf 3.2 1.5 0.47  < 0.0001 RPMI8226 Carf 3.0 3.4 1.14 0.2898
BTZ 17.6 11.6 0.66  < 0.0001 BTZ 16.8 10.5 0.62  < 0.0001
ANBL6 Carf 6.4 4.3 0.67  < 0.0001 ANBL6 Carf 5.7 7.8 1.36 0.0003
BTZ 21.5 14.7 0.69 0.0008 BTZ 21.5 15.2 0.71 0.0143
U266 Carf 5.6 3.2 0.57  < 0.0001 U266 Carf 6.7 7.3 1.10 0.458
BTZ 23.0 13.3 0.58  < 0.0001 BTZ 23.4 12.6 0.54  < 0.0001
  1. HMCLS were treated with 1/3 of their corresponding IC50 of either A) CBR5884 (CBR) or B) NCT-503 (NCT), in combination with either carfilzomib (Carf) or bortezomib (BTZ). The table summarizes the proteasome inhibitors’ (PI) IC50 values obtained from the graphs shown in Additional file 1: Fig. S1A, B and C